Proseek Bio
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Diagnostics and Personalized Medicine
Proseek Bio is advancing a new class of companion diagnostics built on quantitative glycoproteomics—unlocking a critical layer of biology that DNA-based methods and conventional protein assays miss and that is directly linked to drug response. Our mass spectrometry platform precisely measures disease- and drug-associated glycosylation changes, enabling scalable, multi-marker biomarker discovery and deployment well suited to precision medicine in the AI age. Proseek seeks to partner with therapeutic developers to improve patient stratification, enrich clinical trials, and increase probability of success, including enabling asset optimization and rescue strategies. By translating complex glycoprotein signatures into robust, deployable assays, Proseek enables smarter, lower-risk drug development across oncology and other glycoprotein-driven diseases.
Company HQ City:
Fairfield
Company HQ State:
Qld
Company HQ Country:
Australia
Year Founded:
2023
Lead Product in Development:
OC-Triage - for surgical triage of women suspected of ovarian cancer. This blood test can replace a diagnostic surgery.
CEO
Michelle Hill, CEO
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
Early June, 2026
What is your next catalyst (value inflection) update?
multisite clinical readout for a validation study (N=700)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}